WHWK · Whitehawk Therapeutics, Inc.
$4.83
-0.04 (-0.82%)
At close · Aug 20
Market Cap
$275.35M
Shares
57.01M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.83
Open$4.83
Day$4.71–4.93
52W close$1.65–5.10
Avg vol 30d424K
Short int4.4M · 7.8% float · 10.4d
Short vol57%
Last earningsMar 18, 2025
DataAug 2021–Aug 2026
Filing10-Q · Aug 6
Raw chart and full-history price indicators begin at the captured split on Aug 27, 2021; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+39%
above
Price vs 50-day avg
+15%
above
RSI (14)
64
neutral
MACD trend
Positive
52-week position
92%
near high
Momentum
relative strength
1-month return
+26%
trailing
6-month return
+38%
trailing
YTD return
+100%
this year
Relative strength
+26%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
+26% holders QoQ · +29 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.77% of float · ▲ +6.0% MoM · 10.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
78 holders — near 3-yr high, broad support
Squeeze score
70
high risk · 0–100
Fundamentals
Revenue growth
−73%
Y/Y
EPS growth
+86%
Y/Y
Free cash flow
$-98.0M
Balance sheet
$37.6M
net cash
Quant / Vol
risk profile
Volatility
80%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
5.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+39%
Bullish
Price vs 50-day avg
+15%
Bullish
RSI (14)
64
Neutral
MACD trend
Positive
Bullish
52-week position
92%
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
+26% holders QoQ · +29 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.77% of float · ▲ +6.0% MoM · 10.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
78 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $5 · 92%
Range high $5
vs 200-day avg +39%
vs 50-day avg +15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
WHWK
this stock
Whitehawk Therapeutics, Inc.
|
$275.35M | +99.6% | -72.5% | — | 7.8% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
Raw-price comparisons begin at the captured split on Aug 27, 2021; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| WHWK | +3.2% | +26.1% | +37.6% | +25.5% | +99.6% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +5.2% | +22.8% | +26.4% | +23.4% | +87.8% |
Key facts
CIK
1422142
CUSIP
00032Q104
13F (30d)
79 filings
78 filers
Visit website
Investor relations